Posted by Michael Wonder on 14 Sep 2022
Jazz Pharmaceuticals receives SMC approval for reimbursement of Sativex
14 September 2022 - Therapy is for the treatment of spasticity due to multiple sclerosis.
Jazz Pharmaceuticals has announced that Sativex – also known as nabiximols – has been accepted by the SMC for use by NHS Scotland as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis.
